JAK2 and Hodgkins lymphoma: Chromosomal analyses of HRS cells have demonstrated the frequent presence of 9p24.1 amplification, which leads to upregulation of PD-1 ligands and JAK2 [21,22]; this makes PD-1 inhibitors an ideal therapy for HL.